微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 35.55% | 13.38% | 7.35% | 98/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 33.11% | 6.24% | 6.62% | 108/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 31.06% | -0.13% | -1.9% | 114/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 31.66% | -0.58% | 0.97% | 111/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 31.35% | -4.07% | 0.59% | 110/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 31.17% | -2.88% | 0.23% | 117/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 31.1% | -7.92% | -2.34% | 115/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 31.84% | -11.61% | -2.57% | 114/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 32.68% | -12.85% | 1.83% | 111/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 32.09% | -10.3% | -4.97% | 115/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 33.77% | -3.67% | -6.25% | 108/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 36.02% | -2.46% | -3.94% | 109/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 37.5% | -3.5% | 4.81% | 104/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 35.78% | -5.55% | 2.05% | 110/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 35.06% | -11.38% | -5.06% | 104/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 36.93% | -13.06% | -4.97% | 108/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 38.86% | -16.46% | 2.58% | 96/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 37.88% | -25.07% | -4.25% | 111/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 39.56% | -17.21% | -6.86% | 93/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 42.48% | -10.53% | -8.68% | 92/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 46.52% | 2.49% | -7.99% | 73/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 50.56% | 41.22% | 5.79% | 78/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 47.79% | 26.3% | 0.66% | 73/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 47.47% | 23.58% | 4.6% | 79/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 45.38% | 17.85% | 26.77% | 71/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 35.8% | -19.9% | -5.38% | 107/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 37.84% | -18.18% | -1.5% | 80/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 38.41% | -18.74% | -0.25% | 83/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 38.51% | -21.4% | -13.83% | 77/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 44.69% | -0.73% | -3.36% | 80/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 46.25% | 10.6% | -2.17% | 60/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 47.27% | 15.2% | -3.52% | 61/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 49% | 27.17% | 8.83% | 56/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 45.02% | 12.91% | 7.66% | 71/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 41.82% | 5.65% | 1.9% | 55/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 41.04% | 6.28% | 6.51% | 59/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 38.53% | 1.85% | -3.37% | 52/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 39.87% | -2.99% | 0.74% | 68/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 39.58% | -11.96% | 2.52% | 46/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 38.61% | -15.79% | 2.07% | 54/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 37.83% | -10.88% | -7.96% | 45/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |